Contact Us • Home

Clinical Trials >> Pancreas >> EUROPAC2 >> Endpoints

Trial Endpoints

The objective of this study is to determine the efficacy of ANTOX (vers)1.2 and MGCT (Magnesiocard�) compared to placebo in the treatment of pain in patients with hereditary pancreatitis and idiopathic chronic pancreatitis


Primary Outcome

  • Pancreatic pain, defined as the number of days of typical 'pancreatic' pain during one year, calculated by the number of days recorded with any pancreatic pain


Secondary outcomes

  • Intensity of pain recorded using a score (0-10) where 0 is no pain and 10 is the worst pain imaginable.
  • Analgesic consumption assessed using 'morphine equivalents'
  • The number of days spent in hospital due to painful exacerbations of pancreatitis or due to complications arising due to pancreatitis will be obtained from the patient. The clinician responsible for the care of the patient will independently verify this.
  • Quality of Life (QoL) including activities of daily living.


Information | Treatment | Endpoints | Eligibility | Sites - Open | Sites - Interested | Map of Sites | FAQ | Links |

Admin/Site Area

Username:
Password:
Forgotten Password


"The experience and treatment I received at the Royal Liverpool Hospital was so fantastic that I had to tell the people involved with my treatment how marvelous they were, so please would you pass on my thanks and gratitude to Professor Neoptolemos and his team of surgeons, the wonderful doctors and nursing staff" - Anon (Participant in ESPAC-3(v2) trial)

Read more Patient stories